Skip navigation Wisconsin State Legislature
This is the preview version of the Wisconsin State Legislature site.
Please see http://docs.legis.wisconsin.gov for the production version.

Permanent Rules: Promulgation Process Completed (Rules archive prior to 1996 is not complete)

Controlled Substances Board (CSB) Stop grouping [View All]

Name
Relating Clause
  • CR 23-069 (Text)
    Relating to scheduling Zipeprol.
  • CR 23-068 (Text)
    Relating to scheduling Amineptine.
  • CR 23-021 (Text)
    Relating to scheduling Ganaxolone.
  • CR 23-020 (Text)
    Relating to scheduling seven (7) synthetic benzimidazole-opioid substances.
  • CR 23-019 (Text)
    Relating to scheduling Daridorexant.
  • CR 23-018 (Text)
    Relating to scheduling thirty-eight (38) anabolic steroids.
  • CR 22-054 (Text)
    Relating to 4,4’-Dimethylaminorex.
  • CR 22-040 (Text)
    Relating to transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP.
  • CR 22-039 (Text)
    Relating to scheduling Lacosamide.
  • CR 22-038 (Text)
    Relating to scheduling Perampanel.
  • CR 22-037 (Text)
    Relating to scheduling Embutramide.
  • CR 22-036 (Text)
    Relating to scheduling Fospropofol.
  • CR 22-035 (Text)
    Relating to Excluding 6-beta-Naltrexol.
  • CR 22-034 (Text)
    Relating to scheduling Alfaxalone.
  • CR 22-033 (Text)
    Relating to scheduling ten (10) fentanyl related substances.
  • CR 22-032 (Text)
    Relating to scheduling Serdexmethylphenidate.
  • CR 22-016 (Text)
    Relating to scheduling Brorphine.
  • CR 22-014 (Text)
    Relating to scheduling Remimazolam.
  • CR 22-011 (Text)
    Relating to scheduling Crotonyl Fentanyl.
  • CR 21-098 (Text)
    Relating to scheduling oliceridine.
  • CR 20-080 (Text)
    Relating to designating Gabapentin as a monitored drug having a substantial potential for abuse.
  • CR 20-079 (Text)
    Relating to scheduling flualprazolam.
  • CR 20-078 (Text)
    Relating to scheduling of norfentanyl.
  • CR 20-077 (Text)
    Relating to removing FDA approved cannabidiol from schedule V and excluding FDA approved cannabidiol from schedule I.
  • CR 20-076 (Text)
    Relating to scheduling of lemborexant.
  • CR 20-075 (Text)
    Relating to scheduling of cenobamate.
  • CR 20-058 (Text)
    Relating to scheduling of Lasmiditan.
  • CR 20-051 (Text)
    Relating to scheduling of noroxymorphone.
  • CR 20-050 (Text)
    Relating to scheduling of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP.
  • CR 20-049 (Text)
    Relating to scheduling of brexanolone and solriamfetol.
  • CR 20-048 (Text)
    Relating to scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144.
  • CR 20-023 (Text)
    Relating to scheduling isotonitazene and 1P-LSD.
  • CR 20-022 (Text)
    Relating to scheduling MMB-FUBICA and 4F-MDMB-BINACA.
  • CR 19-157 (Text)
    Relating to special use authorizations.
  • CR 19-156 (Text)
    Relating to operation of prescription drug monitoring program.
  • CR 19-012 (Text)
    Relating to scheduling FDA approved cannabidiol.
  • CR 19-011 (Text)
    Relating to scheduling n-ethylpentylone.
  • CR 19-010 (Text)
    Relating to scheduling of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA.
  • CR 18-070 (Text)
    Relating to scheduling para-chloroisobutyryl fentanyl.
  • CR 18-069 (Text)
    Relating to scheduling of MT-45.
  • CR 18-055 (Text)
    Relating to scheduling of oral solutions containing dronabinol.
  • CR 18-024 (Text)
    Relating to excluding from scheduling naldemine.
  • CR 18-023 (Text)
    Relating to scheduling of ortho-fluorofentanyl.
  • CR 18-022 (Text)
    Relating to scheduling of FUB-AMB.
  • CR 17-089 (Text)
    Relating to scheduling 4-Fluoroisobutyryl fentanyl
  • CR 17-088 (Text)
    Relating to scheduling 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA, and MDMB-FUBINACA
  • CR 17-087 (Text)
    Relating to scheduling 4-MePPP and a-PBP
  • CR 17-086 (Text)
    Relating to scheduling MAB-CHMINACA
  • CR 17-085 (Text)
    Relating to scheduling of AB-CHMINACA, AB-PINACA, and THJ-2201
  • CR 17-075 (Text)
    Relating to scheduling cyclopropyl fentanyl.
  • CR 17-040 (Text)
    Relating to scheduling acryl fentanyl.
  • CR 17-028 (Text)
    Relating to the operation of the prescription drug monitoring program.
  • CR 17-023 (Text)
    Relating to scheduling of AH-7921.
  • CR 17-022 (Text)
    Relating to scheduling of eluxadoline.
  • CR 17-021 (Text)
    Relating to scheduling of acetyl fentanyl.
  • CR 17-020 (Text)
    Relating to scheduling of U-47700.
  • CR 17-009 (Text)
    Relating to scheduling of brivaracetam.
  • CR 17-008 (Text)
    Relating to scheduling of AB-FUBINACA and ADB-PINACA.
  • CR 17-007 (Text)
    Relating to scheduling of thiafentanil.
  • CR 16-081 (Text)
    Relating to scheduling of beta-hydroxy thiofentanyl and butyrk fentanyl.
  • CR 16-060 (Text)
    Relating to exclusion of [123I] ioflupane.
  • CR 16-059 (Text)
    Relating to scheduling furanyl fentanyl.
  • CR 15-101 (Text)
    Relating to the operation of the prescription drug monitoring program.
  • CR 15-083 (Text)
    Relating to measurement of controlled substances for purposes of special use authorizations.
  • CR 15-070 (Text)
    Relating to submission of data to the prescription drug monitoring program.
  • CR 15-068 (Text)
    Relating to exclusion of naloxegol.
  • CR 15-009 (Text)
    Relating to scheduling Suvorexant as a schedule IV controlled substance.
  • CR 15-008 (Text)
    Relating to scheduling tramadol as a schedule IV controlled substance.
  • CR 15-007 (Text)
    Relating to rescheduling hydrocodone combination products.